ATE210984T1 - Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen - Google Patents

Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen

Info

Publication number
ATE210984T1
ATE210984T1 AT96100360T AT96100360T ATE210984T1 AT E210984 T1 ATE210984 T1 AT E210984T1 AT 96100360 T AT96100360 T AT 96100360T AT 96100360 T AT96100360 T AT 96100360T AT E210984 T1 ATE210984 T1 AT E210984T1
Authority
AT
Austria
Prior art keywords
serotonin
dopamine receptor
receptor blockers
treat mental
disease
Prior art date
Application number
AT96100360T
Other languages
English (en)
Inventor
Eiichi Otomo
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11550523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE210984(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE210984T1 publication Critical patent/ATE210984T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96100360T 1995-01-12 1996-01-11 Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen ATE210984T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP00319195A JP3274579B2 (ja) 1995-01-12 1995-01-12 脳血管障害に伴う精神症候治療剤

Publications (1)

Publication Number Publication Date
ATE210984T1 true ATE210984T1 (de) 2002-01-15

Family

ID=11550523

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01112981T ATE304855T1 (de) 1995-01-12 1996-01-11 Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
AT96100360T ATE210984T1 (de) 1995-01-12 1996-01-11 Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01112981T ATE304855T1 (de) 1995-01-12 1996-01-11 Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen

Country Status (10)

Country Link
EP (2) EP0730865B1 (de)
JP (1) JP3274579B2 (de)
KR (1) KR100397525B1 (de)
CN (1) CN1088359C (de)
AT (2) ATE304855T1 (de)
CA (1) CA2167004C (de)
DE (2) DE69618047T2 (de)
DK (1) DK0730865T3 (de)
ES (2) ES2249352T3 (de)
PT (1) PT730865E (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
US5902807A (en) * 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
WO1999032108A1 (en) * 1997-12-19 1999-07-01 Akzo Nobel N.V. Org-5222 in the treatment of depression
UA70334C2 (en) * 1998-10-06 2004-10-15 Janssen Pharmaceutica N V Jans BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2007255724B2 (en) * 2006-06-09 2012-05-10 Dainippon Sumitomo Pharma Co., Ltd. Novel tape preparation
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
EP3810099A1 (de) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermales therapeutisches system mit asenapin
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3126331A1 (en) * 2019-01-09 2020-07-16 Ken-ichi YAMADA Pharmaceutical composition for treatment of dementia and cerebrovascular disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4636563A (en) * 1985-09-16 1987-01-13 American Home Products Corporation Antipsychotic γ-carbolines
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
JPH0747574B2 (ja) * 1989-03-03 1995-05-24 大日本製薬株式会社 ピリジン誘導体及びそれを有効成分とする向精神剤
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
NZ236501A (en) * 1989-12-21 1992-12-23 Merrell Dow Pharma Piperidine derivatives and antithrombotic compositions
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
JP3063263B2 (ja) * 1991-07-31 2000-07-12 スズキ株式会社 ミッションケース構造
CA2110251A1 (en) * 1992-11-30 1994-05-31 Koichi Fujimoto Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis
GB9302622D0 (en) * 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
JP3007257B2 (ja) * 1994-03-03 2000-02-07 ローム株式会社 サーマルプリントヘッド
CA2144669A1 (en) * 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
PL189714B1 (pl) * 1995-05-30 2005-09-30 Lilly Co Eli Zastosowanie 2-metylo-4-(4-metylo-1-piperazynylo)-10H-tieno[2,3-b] [1,5]benzodiazepiny

Also Published As

Publication number Publication date
EP0730865B1 (de) 2001-12-19
DE69635213D1 (de) 2006-02-02
DE69635213T2 (de) 2006-11-23
CA2167004C (en) 2006-09-12
KR960028905A (ko) 1996-08-17
EP1181935B1 (de) 2005-09-21
PT730865E (pt) 2002-04-29
CA2167004A1 (en) 1996-07-13
EP0730865A1 (de) 1996-09-11
EP1181935A3 (de) 2002-03-06
ES2249352T3 (es) 2006-04-01
KR100397525B1 (ko) 2003-11-20
CN1088359C (zh) 2002-07-31
DE69618047D1 (de) 2002-01-31
DE69618047T2 (de) 2002-06-20
ATE304855T1 (de) 2005-10-15
DK0730865T3 (da) 2002-04-02
EP1181935A2 (de) 2002-02-27
CN1142945A (zh) 1997-02-19
ES2170176T3 (es) 2002-08-01
JPH08193033A (ja) 1996-07-30
JP3274579B2 (ja) 2002-04-15

Similar Documents

Publication Publication Date Title
DE69618047D1 (de) Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE69133156D1 (de) Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda-rezeptorkomplexes
DE60044152D1 (de) Bupropion Metaboliten zur Behandlung von Angstzuständen
PT721455E (pt) Tetrahidropiridina-(ou 4-hidroxipiperidina) alquilazoles com uma actividade para os receptores sigma e/ou 5ht1a
DE69535498D1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
UY27179A1 (es) Novedosos derivados heterociclicos de los carbonilos y sus usos como ligandos del receptor d3 de la dopamina
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
EA200200766A1 (ru) Замещенные арилпиразины
DE60232029D1 (de) N-ä1h-indol-5-ylünaphthalin-1-sulphonamid-derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems
DK1632483T3 (da) Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
ATE354358T1 (de) Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE60029929D1 (de) VERWENDUNG VON PYRIDAZINO i4,5-(b)ö-INDOLE-1-ACETAMIDE DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS ZUR BEHANDLUNG VON DURCH PERIPHERE BENZODIAZEPINREZEPTOREN-STÖRUNGEN VERURSACHTE KRANKHEITEN
EA199700242A1 (ru) Индазолкарбоксамиды, способ их получения, фармкомпозиция и способ ингибирования 5-нтрецептора
EP0845988A4 (de) Neue kondensierten isochinoline als dopamin-rezeptor-liganden
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE279387T1 (de) Verbindungen zur förderung der neuronendifferenzierung
DE60321606D1 (de) Piperazinylpyrazine als Modulatoren des Serotonin 5-HT2C Rezeptors
ATE246922T1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen
ATE387443T1 (de) Substituierte aminochinuclidin verbindungen und deren verwendung als delta-opioid rezeptor liganden
DE59609219D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification